ArticleNanomedicine (London, England)2025
Intranasal administration of thermoresponsive pterostilbene loaded nanoemulgel confers neuroprotection in a rat model of ischemic stroke.
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop and characterize Pterostilbene (PT)-loaded nanoemulgel (PNEG) and to evaluate its effect in rat model of ischemic stroke.
methodPT-loaded nanoemulsion (PNE) was developed and further coated with chitosan and poloxamer-407 to obtain PNEG. It was characterized for particle size, zeta potential, morphology, entrapment efficiency, viscosity, stability, and ex-vivo mucoadhesive strength. Safety was assessed via in-vitro cytotoxicity assays and ex-vivo nasal mucosal compatibility. The therapeutic efficacy of PNEG was evaluated in a rat model of ischemic stroke, with assessments including neurobehavioral performances, oxidative stress, mitochondrial ultrastructure and complex activity, and pro-inflammatory cytokine levels.
resultsPNEG exhibited particle size of 65.68 ± 0.66 nm with a zeta potential of 9.77 ± 1.2. The formulation demonstrated enhanced mucoadhesive strength and thermoresponsive viscosity, promoting prolonged nasal residence time. In-vitro and ex-vivo assessments confirmed the formulation's biocompatibility and non-toxicity. In-vivo, PNEG significantly enhanced neurological performance, including motor coordination, muscle strength, and cognition, while concurrently reducing oxidative stress, preserving mitochondrial integrity, and suppressing neuroinflammation in hippocampus and cortex of ischemic rats.
conclusionIntranasal PNEG enabled sustained PT delivery with robust neuroprotection in ischemic stroke, highlighting its promise as a clinically translatable strategy for targeted brain therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.